Medidata Solutions announced that it has expanded its accreditation program for services partners to include seven additional Medidata products, in response to the increasing global demand for its product portfolio. The accreditations are available through the Medidata Partner Program, which selects and enables contract research organizations (CROs) and other service providers to manage sponsors’ clinical trials using Medidata products.
Since 2007, Medidata has offered partner accreditations for its Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) system, providing end user training, user and site administration, study build, reporting, outputs, and migration services. With the growing number of global research sponsors implementing a range of Medidata products across the clinical development process, Medidata added the following accreditation options for Medidata Services Partners:
Medidata Balance™—Partners are enabled to provide randomization and trial supply management (RTSM) services using this system. Investigators can access one system—Medidata Rave—for EDC, randomization, and supply management.
Medidata Coder™—Partners offer medical coding services using this centralized enterprise coding solution that is easily integrated with any source system for accelerated coding activities.
Medidata CTMS™—Partners can offer trial management services using modular and flexible tools for study planning, start-up and conduct, along with financial management and trial monitoring. Sponsors benefit from faster site payments, more timely monitor reporting and better visibility into trial milestones.
Medidata Designer®—Partners offer study design services leveraging this study and protocol design solution based on reusable libraries and structured design information to improve protocol quality, expedite EDC setup and reduce amendments.
Medidata Grants Manager®—Partners use this trial budgeting tool for access to the PICAS® database of negotiated costs from investigator grants to rapidly provide customers with accurate trial forecasts and budgets for clinical trials.
Medidata Rave Safety Gateway—Partners automate their customers’ EDC-to-safety-system data transfers using this system to expedite case triage with improved accuracy and completeness of SAE case data, reduce data reconciliation activities and eliminate error-prone phone, paper and fax processes.
Medidata Rave Targeted SDV—Partners can offer more efficient monitoring services using this EDC-based solution to execute targeted (risk-based) source document verification.
Medidata trains, accredits, and supports Medidata Services Partners on its technology so partners can cost-effectively implement and use Medidata products for sponsors’ studies. To become accredited, an organization must first complete required training with a Medidata services team to learn best practices for implementing and using the product. After demonstrating know-how and experience with specific products, Medidata recognizes the organization as a Medidata Services Partner.
Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer services in support of Medidata products. Since then, the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.